A situational analysis of the adoption of oncology, inflammation, and supportive care biosimilars in the United States.
Saved in:
| Title: | A situational analysis of the adoption of oncology, inflammation, and supportive care biosimilars in the United States. |
|---|---|
| Authors: | Shah B; Department of Pharmacy, Boston Medical Center, Boston, MA, USA., Kim J; Medical Affairs, Pfizer, Inc., Collegeville, PA, USA., Wicker A; Akebia Therapeutics, Cambridge, MA, USA., Roth JA; Global Value and Evidence, Pfizer, Inc., New York, NY, USA.; School of Pharmacy, University of Washington, Seattle, WA, USA., Demirjian V; Global Value and Evidence, Pfizer, Inc., New York, NY, USA., Latymer M; Global Medical Affairs, Biosimilars Portfolio, Pfizer, Ltd., Sandwich, UK. |
| Source: | Expert opinion on biological therapy [Expert Opin Biol Ther] 2026 Jan; Vol. 26 (1), pp. 81-92. Date of Electronic Publication: 2026 Jan 30. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101125414 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7682 (Electronic) Linking ISSN: 14712598 NLM ISO Abbreviation: Expert Opin Biol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1744-7682 |
|---|---|
| DOI: | 10.1080/14712598.2026.2621021 |
